secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002757
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Scholar Rock provides 2026 priorities; ~$365M cash; apitegromab BLA resubmission expected in 2026
--------------------------------------------------------------------------------

- Preliminary cash of ~$365M as of Dec 31, 2025; expected runway into 2027.
- Apitegromab BLA resubmission for SMA anticipated in 2026; U.S. launch expected after FDA approval.
- IND cleared for FSHD; Phase 2 FORGE trial initiation and dosing expected mid-2026.
- Subcutaneous apitegromab Phase 1 completed; SRK-439 Phase 1 topline data expected H2 2026.
- EMA MAA decision for apitegromab expected mid-2026; second U.S. fill-finish facility capacity reserved.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/0001104659-26-002757-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000110465926002757/srrk-20260112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002757

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer